Corcept Therapeutics Incorporated (BIT:1CORT)

Market Cap	6.75B -4.8%
Revenue (ttm)	667.04M +12.2%
Net Income	40.49M -64.7%
EPS	0.35 -64.8%
Shares Out	n/a
PE Ratio	166.75
Forward PE	75.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113
Open	59.24
Previous Close	60.56
Day's Range	59.24 - 62.12
52-Week Range	25.50 - 77.84
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 29, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 730
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CORT

Financial Performance

In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.

Financial numbers in USD